In this file
The online program and local IV services have different purposes and costs. That detail matters when comparing the proposed prescription, payment schedule, and access to help.
This provider file follows the company’s published material and the questions it leaves open. It covers the care arrangement, price, cancellation boundaries, and contact routes; it does not certify the business or determine whether a treatment is appropriate for a particular person.
Understand the care arrangement
Ivologist’s menu combines weight-management telehealth, hormone-related care, and local wellness or IV services. Its own disclaimer states that the telehealth service does not replace primary care. Ask which clinician will manage the weight-management program and what ongoing follow-up belongs to it.
Name the organizations involved in your own plan. The website operator, clinical practice, and pharmacy may be separate businesses. A patient should know which one is responsible for a medical decision, which holds the account, and which handles the medication.
Read the price in its proper context
Ivologist describes cash-pay programs, possible financing, and HSA/FSA eligibility for some treatments. The reviewed homepage does not establish one universal medication-inclusive price. Obtain the full proposal, including any deposit, testing, and recurring charges, and check reimbursement eligibility with the plan administrator.
Record the total paid today, the period it buys, and the next payment. If a figure is expressed per month but collected for several months, keep both numbers in the comparison. Our price-comparison worksheet helps separate a low initial figure from the continuing commitment.
Find the cancellation boundary
Before accepting financing or a deposit, ask what happens if treatment is declined, changed, or stopped. Ending a program may not cancel a separate financing obligation. Get the relevant cancellation terms for the telehealth pathway rather than borrowing rules from a local appointment or IV service.
A useful request names the next renewal and the current order separately. Ask for confirmation of both the effective cancellation date and the pharmacy status. Instructions for stopping or changing the medicine itself need to come from the treating professional.
Identify the actual prescription
The website explicitly notes that compounded medicines are not FDA-approved. Confirm whether the proposed weight-management prescription is compounded, its exact formulation, and the pharmacy assigned to it. A wider wellness menu does not establish clinical evidence for combining multiple treatments.
FDA approval concerns a particular drug product. A compounded preparation has not received that approval, and evidence for a different formulation cannot guarantee an individual result. Read the product-approval explanation and ask questions about the exact medicine proposed.
Contact and account help
Ivologist’s published contact number is (210) 436-8822.
Specify whether the question concerns telehealth weight management or a local service.
Start from the official Ivologist website to find its verified patient-account navigation. We have not signed into a private portal or measured its support response. Do not share passwords, access codes, payment-card details, or medical records with a review site.
Bring one concrete question to the consultation
Which services belong to my telehealth weight-management plan, and what obligations remain if I stop a financed or prepaid program?
Write the answer beside the proposed prescription and agreement. If it describes a different product, an expired promotion, or a plan you are not eligible for, ask for clarification. Our pre-purchase checklist can help keep those questions organized.
Source notes
Provider material describes the company’s own offer. Official medical references explain clinical and regulatory context; they do not endorse this publication or its commercial partner.
- Online GLP-1, TRT, HRT & IV Therapy | Ivologist ↗Provider-published information · Checked September 22, 2026
- FDA: concerns with unapproved GLP-1 drugs ↗Regulatory / public agency · Checked September 22, 2026
- FDA: risks of compounded drugs ↗Regulatory / public agency · Checked September 22, 2026